Rituximab (anti-CD20)

Catalog No.A2009 Synonyms: IDEC-C2B8

For research use only.
Not for use in humans.

Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

Rituximab (anti-CD20)

Selleck's Rituximab (anti-CD20) has been cited by 7 Publications

Purity & Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
CD20 [1]
In vitro

Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab[3]. Rituximab can induce death of malignant B cell lines in vitro. Th strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples[2]. CD20-binding capacity of rituximab is dose-dependentv[3].

In vivo A number of in vivo tumor models suggest the anti-tumor activity of rituximab is dependent, at least in part, on complement[2]. Rituximab can deplete B cells for several months and, as such, could represent an effective therapy for B cell-mediated autoimmune diseases. Rituximab is now widely used in onco-haematology and is currently in development in several autoimmune diseases[5].

Protocol (from reference)

Cell Research:
  • Objective: Antibody-dependent cellular cytotoxicity assays (ADCC)
    Cells: BJAB Burkitt’s lymphoma (BL) line, Karpas 422, DOHH-2 and WSU-NHL follicular lymphoma cell lines, natural killer (NK) cells (isolated from lymphoma patients' mononuclear cells)
    Concentrations: 2 μg/mL
    Incubation Time: 4 h
    Method: 2×106 lymphoma cells were loaded with 51Cr by incubation for 1 hour with 3.7 MBq (100 μCi) 51Cr. 104 lymphoma cells were incubated with or without 2 μg/mL rituximab and increasing amounts of NK cell population for 4 hours at 37°C in complete medium. The 100 μL of cell supernatant was then collected and counted in a γ-counter.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/10845926

    Objective: Complement-mediated cell lysis
    Cells: Lymphoma B cells
    Concentrations: 0, 0.02, 0.2, 2, 20 μg/mL
    Incubation Time: 2 h
    Method: Lymphoma B cells were purified from lymph node biopsies of patients with B-cell lymphoma. Rituximab was added to tumor cells (1×106 /mL) in complete medium supplemented by human serum, inactivated or not by incubation at 56°C for 30 minutes. After 2 hours at 37°C, cell lysis was determined by PI staining of cells and analysis by flow cytometry.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/12393572

    Rituximab can apply to immunodeficient mice (eg: SCID mice), lymphoma cell lines and other related assays (Only for Reference)

Animal Research:
  • Objective: To study the mechanisms of follicular lymphoma’s resistance to rituximab
    Animal Models: Female CB17 severe combined immunodeficient(SCID) mice were injected (s.c.) with rituximab-resistant lymphoma cells (derived from a human FL)
    Formulation: --
    Dosages: 10mg/kg, weekly
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/19188155

    Objective: To investigate the therapeutic effect of rituximab in combination with L19-IL2 on B-cell malignancies
    Animal Models: CB17/lcr severe combined mmunodeficiency (SCID) mice were injected (s.c.) Ramos or DoHH-2 lymphoma cells
    Formulation: saline
    Dosages: 200 μg
    Administration: i.v.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/19005180

    Rituximab can apply to immunodeficient mice (eg: SCID mice), lymphoma cell lines and other related assays (Only for Reference)

Product Details

CAS No. 174722-31-7
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: buy Rituximab (anti-CD20) | Rituximab (anti-CD20) supplier | purchase Rituximab (anti-CD20) | Rituximab (anti-CD20) cost | Rituximab (anti-CD20) manufacturer | order Rituximab (anti-CD20) | Rituximab (anti-CD20) distributor